Navigation Links
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Date:5/24/2009

>

In the study, ACTEMRA was generally well-tolerated and the overall safety profile after two years of treatment with ACTEMRA was consistent with previously reported data. Full data from this two-year study will be submitted to the U.S. Food and Drug Administration (FDA) and for presentation at a future international scientific meeting.

One-year LITHE data have been accepted for presentation at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark.

About the LITHE Study

The LITHE study was a three-arm, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of ACTEMRA (8 mg/kg and 4 mg/kg) plus methotrexate compared with placebo plus methotrexate in RA patients. Patients in the LITHE study received either ACTEMRA intravenously every four weeks plus methotrexate weekly or placebo infusions every four weeks plus methotrexate weekly. The LITHE study included nearly 1,200 patients from 137 sites in 15 countries, including the United States. The study aimed to show the inhibition of structural damage at the joints, as demonstrated by changes in validated radiographic parameters. The study also examined the improvement in physical function and disease signs and symptoms.

One-year data from the study showed the mean change in the combined Genant-modified Sharp score(3), which assesses progression of both joint erosion and joint space narrowing, was lower among ACTEMRA (8 mg/kg and 4 mg/kg) plus methotrexate-treated patients versus methotrexate plus placebo-treated patients (0.3, 0.3 versus 1.1, respectively; p<0.001). In addition, the one-year study results showed that 85 percent and 81 percent of patients treated with ACTEMRA (8 mg/kg or 4 mg/kg, respectively) experienced no progression of either joint erosion or joint space narrowing, as measured by the Genan
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
2. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
5. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
10. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
11. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015  Astellas today announced ... evaluating the efficacy and safety of intravenous (IV) ... sulfate), under development for adults with candidemia and ... the study demonstrated that the trial did not ... treatment response in isavuconazole-treated patients at the end ...
(Date:7/29/2015)... , July 29, 2015  Unilife Corporation ("Unilife" or ... a developer, manufacturer and supplier of injectable drug delivery ... strategy that provides the Company with flexibility and control ... Unilife has signed an equity purchase agreement for up ... ("LPC"), a Chicago -based institutional investor, ...
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
... avoid damage to heart ... ... plaque,and blood clot that break loose during percutaneous coronary intervention,(PCI) has failed ... with acute coronary syndromes, a condition that,encompasses unstable angina and a type ...
... bests clopidogrel, CHICAGO, March 29 Prasugrel ... with acute coronary syndromes (ACS) more,effectively than clopidogrel, ... risk of,thrombosis, or blood clotting, inside the coronary ... Trial to Assess Improvement in Therapeutic,Outcomes by Optimizing ...
Cached Medicine Technology:Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 2Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 3TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay ... taxpayer money to fund the state’s large prison system, which has amassed largely enough ... rates of incarceration. In light of President Obama’s recent reduction of non violent drug ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Ocean Hills Recovery ... including the very rare “no recommendations.” No recommendations means CARF found no areas in ... a notation that less than 3% of all facilities receive. In addition, Ocean Hills ...
(Date:7/30/2015)... ... July 30, 2015 , ... The New Jersey Innovation ... Jersey Department of Health, has received a $2.9 million grant from the Office ... Department of Health and Human Services (HHS). NJII will help the Department of ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of ... easy to apply lotion or medication to a hard-to-reach area. This invention is patented. ... medication to the back, and provides thorough coverage. The product would prevent the user ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos ... their health in his new self-help book, “ Consciously Healing our Webs of Health, ... a simple message: “If we take responsibility for ourselves, we can create better realities.” ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3
... researchers used brain scans to try and study the biology ... attention the brain pays to the expected pain // determines ... to suggesting that simple diversions could alleviate the misery. ... of a new field called neuroeconomics that uses brain imaging ...
... first ever-national survey of autism in the US it was ... confirms the wide spreading of the disorder that is afflicting ... 175. // ,The new estimate contraindicates with the ... two decades ago, This has bought about an argument as ...
... view to appeasing the public about bird flu and to ... powerful medium of advertisements aired over radio // and television ... consume, if it is properly cooked. ,The advertisements ... event of the virus spreading to the U.S. ...
... a beneficial and healthy activity. With the emphasis slowly, but ... nothing like a bit of gardening to rev up your ... at Northwestern Memorial Hospital in Chicago says that the best ... you bend down at your knees. "It's going to give ...
... even the aid of the computers are sought in order ... very handy //as they have the ability to perform difficult ... any rest. They are good at handling long and complex ... handy to search for a cure against bird flu. Mostly ...
... Restless Legs Syndrome or the shaking leg syndrome is a common ... sensation in their legs//. For the first time Europe has approved ... the nerves and causes aches and pains. Statistics show that about ... ,The license was given by the European Medicines Agency. As of ...
Cached Medicine News:Health News:Burn Away Calories In Your Garden 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... of Pacemakers, Ela presents the most advanced ... a passport, will take your patients further, ... delivering powerful monitoring. ELA dual chamber ... atrial tracking modes in patients who may ...
Medicine Products: